1525 GMT - GSK's 2025 outlook is promising, fueled by the sales growth expectations for its specialty medicines, Quilter Cheviot healthcare analyst Sheena Berry says in a note. The British pharma giant's clinical results for its chronic-cough drug candidate and regulatory decisions on a potential comeback of its blood-disorder treatment Blenrep are crucial for the group's future trajectory, she says. Shares are up 6.7% at 14.73 pounds.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 10:25 ET (15:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。